Based on our findings, aspirin is expected to lower SSAT activity in early prostate tumours, therefore enhancing the sensitivity of the tumour cells to the drug and finally preventing tumour development via changing cellular polyamine content. This evidence concerns the gene SAT1 and prostate neoplasm.